Judgment_paragraph 87 · Commission of the European Communities v CEVA Santé Animale SA and Pfizer Enterprises Sàrl (C-198/03 P)

87That position on the maintenance of the use of progesterone for therapeutic or zootechnical purposes constituted a stage which necessarily had to precede the taking of a position on the establishment of an MRL for that substance, since an MRL may be established for a pharmacologically active substance only if that substance is intended to be placed on the market (Case C-248/99 P France v Monsanto and Commission [2002] ECR I-1, paragraph 80).